ClinicalTrials.gg
TerminatedNCT01145417Updated Jan 28, 2021Results posted

Pregabalin Trial In HIV Neuropathic Pain

A Phase 3 interventional study of pregabalin (Lyrica) in HIV-1 Infection and Neuropathic Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 29 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
217
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.

Enrollment
11th of 50
217 · median 109
Started
2010
with 3 others
Phase 3
18 of 50
1 open now
Registered
22nd of 50
by date
Lead sponsor
12 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing pregabalin in Neuralgia, this one is the 11th largest by enrollment, is one of 4 that started in 2010, is one of 18 in phase 3, and was the 22nd registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing pregabalin in Neuralgia, or all of them as a file.
02

Study summary

This study examines the safety of pregabalin over a 6 month period in patients with neuropathic pain associated with HIV infection as an extension of another trial that tests the efficacy of pregabalin.

Read the detailed description

The parent double blind study was stopped at interim analysis due to lack of efficacy and therefore this open label extension study was also terminated simultaneously on April 2, 2012; the termination was unrelated to any safety findings that could impact patient health.

03

Conditions studied

  • HIV-1 Infection
  • Neuropathic Pain

Browse trials for

Keywords

  • peripheral neuropathic pain
  • pregabalin
  • safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who participated in the preceding A0081244 double-blind trial and completed at least through Visit 9 of that trial.

Subjects with painful distal sensory polyneuropathy (DSP) interested in treatment based on investigator's clinical judgment.

Subjects who had acceptable tolerability of study drug in A0081244.

Exclusion criteria

Exclusion Criteria:

  • or unstable conditions that, in the opinion of the investigator, would compromise participation in the study. This includes, for example, medical conditions such as, but not limited to: hepatic, renal, respiratory, hematological, immunological, cardiovascular diseases, arrhythmia, inflammatory or rheumatologic disease, active infections, symptomatic peripheral vascular disease, psychiatric illness, and untreated endocrine disorders.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • Active Acquired Immune Deficiency Syndrome (AIDS)- defining Opportunistic Infection (OI) that requires hospitalization.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Pregabalin (Lyrica)

    Drug: pregabalin (Lyrica)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to 30 days after last dose of study treatment

Secondary outcomes

  1. Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire

    WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a Human Immunodeficiency Virus (HIV) neuropathy pain. Number of participants who responded "Yes/No" to Question 1: Are you currently employed (working for pay)? are reported.

    Time frame: Baseline, Week 24

  2. Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire

    WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a HIV neuropathy pain. Question 2 and 3 assesses absenteeism as: Hours of work missed in past 7 days due to leg/foot pain or other reason, respectively. Question 4 assesses presenteeism as: Hours of work performed in past 7 days.

    Time frame: Baseline, Week 24

  3. Productivity and Activity Impairment Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire

    WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a HIV neuropathy pain. Question 5 and 6 assesses: How much leg/foot pain affect productivity and daily activity, respectively in past 7 days? on 11-point scale, where 0 (not affected/no impairment) to 10 (completely affected/impaired).

    Time frame: Baseline, Week 24

  4. 36-Item Short-Form Health Survey (SF-36)

    SF-36 is a standardized survey evaluating 8 domains of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). Two summary scores include Physical Component (Ph C) and Mental Component (Mn C). The score for a section is an average of the individual question scores. Score range for domain scores and summary scores: 0-100 (100=highest level of functioning).

    Time frame: Baseline, Week 24

  5. Visual Analogue Scale for Pain (VAS-pain)

    Participants rated the severity of HIV neuropathy pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Time frame: Baseline, Week 4, 8, 12, 16, 20, 24

  6. Number of Participants With Categorical Scores on Patient Global Impression of Change (PGI-C)

    PGI-C: participant rated instrument to measure participant's change in overall status since the start of the study, on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Number of participants in each category are reported.

    Time frame: Week 24

  7. Number of Participants With Response to Sheehan-Suicidality Tracking Scale (S-STS) Mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories

    S-STS:8-item clinician/participant administered prospective rating scale to assess TE suicidal(Su) ideation(ID),behavior(BHV).Items 1a,2-6,7a,8 scored on 5-point Likert scale 0(not at all) to 4(extremely). Items 1,1b,7 require yes/no response. S-STS total score range 0-30. Lower score=reduced Su tendency. Responses on S-STS were mapped to Columbia Classification Algorithm of Suicide Assessment(C-CASA) as 1:Completed Su; 2: Su attempt; 3: Preparatory acts; 4: Su ID; 5: Self-injurious (SI) BHV, intent unknown; 6: Not enough information; 7: SI BHV, no Su intent; 8: Other, no deliberate self harm.

    Time frame: Baseline up to Week 25

  8. Number of Participants With Response to Patient Health Questionnaire-8 (PHQ-8)

    PHQ-8: 8-item self-administered validated subset of PHQ-9, which comprises first 8 items of measure. Participant rated "Over past 2 weeks, how often bothered by any of following problems?": little interest in doing things(1); feeling down(2); trouble falling or staying asleep/sleeping too much(3); feeling tired(4); poor appetite/overeating(5); feeling bad about self(6); trouble concentrating(7); moving or speaking slowly or being so fidgety/moving around more than usual(8). Each item scored on scale of 0(not at all)-3(nearly every day). Total score range: 0-24, higher score=greater severity.

    Time frame: Baseline

07

Results

Posted Jun 27, 2013
Limitations and caveats
The parent double blind trial A0081244 (NCT01049217) was stopped at interim analysis due to lack of efficacy and therefore this open label extension study was also terminated.

Participant flow

Following completion of Visit 9 (Day 57) of double-blind trial A0081244 (NCT01049217), participants who met eligibility criteria initiated open-label treatment in the current trial A0081251 (NCT01145417).

Participant flow — Overall Study
MilestonePregabalin-PregabalinPlacebo-Pregabalin
Started108109
Completed6762
Not completed4147
Withdrew: Death10
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject12
Withdrew: Pregnancy10
Withdrew: Adverse event01
Withdrew: Study terminated by sponsor3543
Withdrew: Other10

Outcome measures

PrimaryNumber of Participants With Treatment Emergent (TE) Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to 30 days after last dose of study treatment
Reported as:
Number · participants
Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPregabalin-PregabalinPlacebo-Pregabalin
AEs6770
SAEs43
SecondaryNumber of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire

WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a Human Immunodeficiency Virus (HIV) neuropathy pain. Number of participants who responded "Yes/No" to Question 1: Are you currently employed (working for pay)? are reported.

Time frame:
Baseline, Week 24
Reported as:
Number · participants
Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire
participantsPregabalin-PregabalinPlacebo-Pregabalin
Baseline, employed (n=52,51)1211
Baseline, unemployed (n=52,51)4040
Week 24, employed (n=103,104)3527
Week 24, unemployed (n=103,104)6877
SecondaryAbsenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire

WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a HIV neuropathy pain. Question 2 and 3 assesses absenteeism as: Hours of work missed in past 7 days due to leg/foot pain or other reason, respectively. Question 4 assesses presenteeism as: Hours of work performed in past 7 days.

Time frame:
Baseline, Week 24
Reported as:
Mean · hours
Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire
hoursPregabalin-PregabalinPlacebo-Pregabalin
Baseline, hours missed,leg/foot pain (n=12,11)2.25 ± 6.8770.82 ± 2.401
Baseline, hours missed,other reason (n=12,11)3.42 ± 6.5010.91 ± 1.700
Baseline, hours worked (n=12,11)35.58 ± 15.16330.36 ± 18.112
Week 24, hours missed,leg/foot pain (n=35,28)2.17 ± 4.9562.32 ± 8.533
Week 24, hours missed,other reason (n=35,28)9.20 ± 21.6047.71 ± 14.976
Week 24, hours worked (n=35,28)41.51 ± 20.03434.86 ± 21.329
SecondaryProductivity and Activity Impairment Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire

WPAI: 6-question participant rated questionnaire to determine the degree to which SHP affected work productivity while at work and affected activities outside of work. It assesses amount of absenteeism, presenteeism and daily activity impairment attributable to a HIV neuropathy pain. Question 5 and 6 assesses: How much leg/foot pain affect productivity and daily activity, respectively in past 7 days? on 11-point scale, where 0 (not affected/no impairment) to 10 (completely affected/impaired).

Time frame:
Baseline, Week 24
Reported as:
Mean · Units on a scale
Productivity and Activity Impairment Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire
Units on a scalePregabalin-PregabalinPlacebo-Pregabalin
Baseline, productivity affected (n=12,10)4.42 ± 2.8432.40 ± 2.716
Baseline, daily activity affected (n=52,51)3.48 ± 2.8463.47 ± 2.935
Week 24, productivity affected (n=35,29)2.17 ± 1.9172.24 ± 2.415
Week 24, daily activity affected (n=103,104)2.51 ± 2.3302.72 ± 2.653
Secondary36-Item Short-Form Health Survey (SF-36)

SF-36 is a standardized survey evaluating 8 domains of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). Two summary scores include Physical Component (Ph C) and Mental Component (Mn C). The score for a section is an average of the individual question scores. Score range for domain scores and summary scores: 0-100 (100=highest level of functioning).

Time frame:
Baseline, Week 24
Reported as:
Mean · Units on a scale
36-Item Short-Form Health Survey (SF-36)
Units on a scalePregabalin-PregabalinPlacebo-Pregabalin
Baseline: Ph Fn (n=51,53)73.14 ± 22.67175.47 ± 22.729
Baseline: R-P (n=51,53)75.49 ± 22.87371.93 ± 27.616
Baseline: BP (n=51,53)68.86 ± 20.43068.87 ± 26.010
Baseline: GH (n=51,53)72.25 ± 20.36968.79 ± 20.411
Baseline: Ph C (n=51,53)47.68 ± 7.26846.85 ± 9.578
Baseline: Vit (n=51,53)71.57 ± 19.41873.11 ± 17.660
Baseline: So Fn (n=51,53)78.92 ± 18.11382.08 ± 18.911
Baseline: R-E (n=51,53)81.05 ± 20.07579.87 ± 23.367
Baseline: MnH (n=51,53)76.27 ± 18.07980.00 ± 15.411
Baseline: Mn C (n=51,53)51.41 ± 8.91552.71 ± 7.763
Week 24: Ph Fn (n=103,104)70.34 ± 27.59475.24 ± 25.086
Week 24: R-P (n=103,104)71.18 ± 24.92772.96 ± 26.680
Week 24: BP (n=102,104)69.57 ± 22.55072.19 ± 23.033
Week 24: GH (n=103,104)73.14 ± 19.93371.31 ± 19.879
Week 24: Ph C (n=102,104)47.28 ± 8.77048.48 ± 8.634
Week 24: Vit (n=103,104)68.51 ± 18.50266.29 ± 20.039
Week 24: So Fn (n=103,104)79.98 ± 20.88381.85 ± 20.304
Week 24: R-E (n=103,104)74.19 ± 27.02975.80 ± 25.640
Week 24: MnH (n=103,104)76.21 ± 18.19675.77 ± 18.588
Week 24: Mn C (n=102,104)50.15 ± 10.39449.72 ± 9.884
SecondaryVisual Analogue Scale for Pain (VAS-pain)

Participants rated the severity of HIV neuropathy pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

Time frame:
Baseline, Week 4, 8, 12, 16, 20, 24
Reported as:
Mean · millimeter (mm)
Visual Analogue Scale for Pain (VAS-pain)
millimeter (mm)Pregabalin-PregabalinPlacebo-Pregabalin
Baseline (n=107,108)40.6 ± 26.5540.7 ± 26.57
Week 4 (n=106,106)33.1 ± 25.1433.1 ± 27.11
Week 8 (n=100,101)27.4 ± 21.0127.8 ± 24.25
Week 12 (n=89,88)24.1 ± 22.4123.8 ± 23.45
Week 16 (n=85,81)22.6 ± 20.8222.6 ± 25.32
Week 20 (n=72,67)17.2 ± 19.1817.7 ± 22.78
Week 24 (n=103,104)22.2 ± 22.5423.7 ± 23.94
SecondaryNumber of Participants With Categorical Scores on Patient Global Impression of Change (PGI-C)

PGI-C: participant rated instrument to measure participant's change in overall status since the start of the study, on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Number of participants in each category are reported.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With Categorical Scores on Patient Global Impression of Change (PGI-C)
participantsPregabalin-PregabalinPlacebo-Pregabalin
Very Much Improved4137
Much Improved4347
Minimally Improved1616
No Change23
Minimally Worse10
Much Worse01
Very Much Worse00
SecondaryNumber of Participants With Response to Sheehan-Suicidality Tracking Scale (S-STS) Mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories

S-STS:8-item clinician/participant administered prospective rating scale to assess TE suicidal(Su) ideation(ID),behavior(BHV).Items 1a,2-6,7a,8 scored on 5-point Likert scale 0(not at all) to 4(extremely). Items 1,1b,7 require yes/no response. S-STS total score range 0-30. Lower score=reduced Su tendency. Responses on S-STS were mapped to Columbia Classification Algorithm of Suicide Assessment(C-CASA) as 1:Completed Su; 2: Su attempt; 3: Preparatory acts; 4: Su ID; 5: Self-injurious (SI) BHV, intent unknown; 6: Not enough information; 7: SI BHV, no Su intent; 8: Other, no deliberate self harm.

Time frame:
Baseline up to Week 25
Reported as:
Number · participants
Number of Participants With Response to Sheehan-Suicidality Tracking Scale (S-STS) Mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories
participantsPregabalin-PregabalinPlacebo-Pregabalin
Suicide attempt: 201
Preparatory acts toward suicidal behavior: 301
Suicidal ideation: 449
SecondaryNumber of Participants With Response to Patient Health Questionnaire-8 (PHQ-8)

PHQ-8: 8-item self-administered validated subset of PHQ-9, which comprises first 8 items of measure. Participant rated "Over past 2 weeks, how often bothered by any of following problems?": little interest in doing things(1); feeling down(2); trouble falling or staying asleep/sleeping too much(3); feeling tired(4); poor appetite/overeating(5); feeling bad about self(6); trouble concentrating(7); moving or speaking slowly or being so fidgety/moving around more than usual(8). Each item scored on scale of 0(not at all)-3(nearly every day). Total score range: 0-24, higher score=greater severity.

Time frame:
Baseline
Reported as:
Number · participants
Number of Participants With Response to Patient Health Questionnaire-8 (PHQ-8)
participantsPregabalin-PregabalinPlacebo-Pregabalin
Little interest in things: Not at All5967
Little interest in things: Several Days3125
Little interest in things: More Than Half the Days149
Little interest in things: Nearly Every Day37
Feeling down: Not at All8479
Feeling down: Several Days1821
Feeling down: More Than Half the Days56
Feeling down: Nearly Every Day02
Trouble with sleep: Not at All5759
Trouble with sleep: Several Days3340
Trouble with sleep: More Than Half the Days144
Trouble with sleep: Nearly Every Day35
Feeling tired: Not at All5253
Feeling tired: Several Days4340
Feeling tired: More Than Half the Days1214
Feeling tired: Nearly Every Day01
Poor appetite/overeating: Not at All7571
Poor appetite/overeating: Several Days2426
Poor appetite/overeating: More Than Half the Days55
Poor appetite/overeating: Nearly Every Day36
Feeling bad about self: Not at All9288
Feeling bad about self: Several Days1213
Feeling bad about self: More Than Half the Days23
Feeling bad about self: Nearly Every Day14
Trouble concentrating: Not at All7984
Trouble concentrating: Several Days2320
Trouble concentrating: More Than Half the Days23
Trouble concentrating: Nearly Every Day31
Move or speak slow/fidgety: Not at All8786
Move or speak slow/fidgety: Several Days1816
Move or speak slow/fidget: More Than Half the Days03
Move or speak slow/fidgety: Nearly Every Day23

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin-Pregabalin—4/108 (3.7%)35/108 (32.4%)
Placebo-Pregabalin—3/109 (2.8%)50/109 (45.9%)
Most frequent serious events
Most frequent serious events
EventPregabalin-PregabalinPlacebo-Pregabalin
CellulitisInfections and infestations1/1080/109
HIV infectionInfections and infestations1/1080/109
Muscle strainInjury, poisoning and procedural complications1/1080/109
Transient ischaemic attackNervous system disorders1/1080/109
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders0/1081/109
GastroenteritisInfections and infestations0/1081/109
Facial bones fractureInjury, poisoning and procedural complications0/1081/109
Kaposi's sarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1081/109
Most frequent other events
Most frequent other events
EventPregabalin-PregabalinPlacebo-Pregabalin
DizzinessNervous system disorders10/10819/109
SomnolenceNervous system disorders9/10814/109
HeadacheNervous system disorders5/1088/109
InfluenzaInfections and infestations5/1087/109
Back painMusculoskeletal and connective tissue disorders6/1082/109
Oedema peripheralGeneral disorders2/1086/109
PharyngitisInfections and infestations2/1086/109

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pregabalin-PregabalinPlacebo-PregabalinTotal
Mean42.4 ± 8.843.5 ± 7.942.9 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin-PregabalinPlacebo-PregabalinTotal
Female7168139
Male374178
08

Study locations

29 sites
  • Southwest Center for HIV/AIDS
    Phoenix, Arizona 85006, United States
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Providence Clinical Research
    Burbank, California 91505, United States
  • Desert Medical Group, Inc., dba Desert Oasis Healthcare Medical Group
    Palm Springs, California 92262, United States
  • Desert Medical Group, Inc., dba Desert Oasis Helathcare Medical Group
    Palm Springs, California 92262, United States
  • University of California San Diego
    San Diego, California 92103, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Neuroscience Consultants, LLC
    Aventura, Florida 33180, United States
  • South Florida Medical Research
    Aventura, Florida 33180, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Riesgo de Fractura S.A.
    Bogota D.C., Cundinamarca, Colombia
  • Asistencia Cientifica de Alta Complejidad
    Bogota, Cundinamarca 0000, Colombia
  • Surakshaka Multispeciality Hospital
    Hyderabad, Andhra Pradesh 500 072, India
  • Infectious Disease Clinic
    Ahemdabad, Gujarat 380 009, India
  • Deenanath Mangeshkar Hospital and Research Centre
    Pune, Maharashtra 411 004, India
  • Hospital Nacional Dos de Mayo
    Lima, L 01, Peru
  • RCMI-Clinical Research Center
    Rio Piedras, 00935, Puerto Rico
  • MediSynergy
    Port Elizabeth, Eastern Cape 6065, South Africa
  • Worthwhile Clinical Trials (WWCT), Lake View Hospital
    Benoni, Gauteng 1500, South Africa
  • Toga Laboratory
    Johannesburg, Gauteng 1610, South Africa
  • Drs Essack and Mitha
    Johannesburg, Gauteng 2113, South Africa
  • Pretoria West Hospital
    Pretoria West, Gauteng 0117, South Africa
  • Dr J. Reddy's Surgery
    Stanger, KwaZulu Natal 4450, South Africa
  • University of Cape Town
    Cape Town, Western Cape 7925, South Africa
  • Synapta Clinical Research Centre
    Durban, 4001, South Africa
  • Paarl Research Center
    Paarl, 7626, South Africa
  • Be Part Yoluntu Centre
    Paarl, 7646, South Africa
  • South East Asia Research Collaboration with Hawaii
    Bangkok, 10330, Thailand
  • Neurology unit, Department of Medicine,
    Bangkok, 10400, Thailand
09

References and documents

Publications

  • Simpson DM, Rice AS, Emir B, Landen J, Semel D, Chew ML, Sporn J. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. Pain. 2014 Oct;155(10):1943-54. doi: 10.1016/j.pain.2014.05.027. Epub 2014 Jun 4. PubMed 24907403 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2010
First posted
Jun 16, 2010
Start
Jul 2010
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Jun 27, 2013
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01145417
Responsible party
Sponsor
First posted
Jun 16, 2010
Start date
Jul 2010
Primary completion
May 2012
Completion
May 2012
Results posted
Jun 27, 2013
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion